LASIK offers good long-term results for high myopes

Article

LASIK for myopia over -10 D is both safe and effective in the long-term.

LASIK for myopia over -10 D is both safe and effective in the long-term, according to a report published in the January issue of the American Journal of Ophthalmology.

Jorge Alio of the Miguel Hernandez University Medical School, Alicante, and of the VISSUM, Instituto Oftalmologico de Alicante, Spain and colleagues from Ankara University of Medicine, Turkey enrolled 196 highly myopic eyes of 118 patients who, preoperatively, required at least 10 D corrections in order to achieve 20/20 vision. All patients were available to follow-up 10 years after initial surgery.

Prior to surgery, uncorrected vision was 77% of best corrected visual acuity (BCVA). Just 5% of eyes lost more than 2 lines BCVA, 40% were able to avoid wearing spectacles and 61% were within ±2 D at 10 years. Only two eyes (1%) developed corneal ectasia.

This study demonstrates that LASIK can offer excellent results in terms of predictability, efficacy and safety for highly myopic patients over the long-term.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.